You are viewing: India Human Organoids Market analysis
Part of: Human Organoids Market (Global)

The India Human Organoids Market was valued at $31.4 Million in 2024 and projected to reach to $70.7 Million by 2029, representing a compound annual growth rate of CAGR 17.7%. India's human organoids market is positioned for exceptional growth, driven by substantial investments in regenerative medicine infrastructure and increasing recognition of organoid technology's potential in drug development and disease research.

India Human Organoids Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

India Human Organoids Market Trends and Insights

  • This accelerated expansion in India reflects increasing investments in regenerative medicine research, growing pharmaceutical and biotechnology sector capabilities, and rising government support for advanced healthcare innovation.
  • India's position as a global hub for contract research and development is driving adoption of organoid technologies for drug testing and disease modeling. The human organoids market in India is being propelled by several factors including the country's expanding life sciences infrastructure, cost-effective research capabilities, and a large patient population driving demand for personalized medicine solutions.
  • India's pharmaceutical industry is increasingly leveraging organoid technology for preclinical testing and therapeutic development.
  • Between 2024 and 2029, India is expected to capture significant market share within the Asia Pacific region, supported by collaborations between academic institutions, government research bodies, and private biotech firms focused on advancing organoid-based applications in disease research and drug discovery..

Key Market Statistics

  • CAGR (2024-2029) CAGR 17.7%
  • Market Size, 2024 ~USD 31.4 Million
  • Forecast, 2029 ~USD 70.7 Million
  • Country India

India Human Organoids Market Overview

Rapid Market Expansion :

India's human organoids market is projected to grow from $31.4 million in 2024 to $70.7 million by 2029, with a CAGR of 17.7%, significantly outpacing the global growth rate of 14.4%.

Government Support & Investment :

Increased government initiatives and funding for regenerative medicine research, coupled with favorable biotech policies, are accelerating organoid research and commercialization across Indian institutions.

Biotech Sector Growth :

India's expanding pharmaceutical and biotechnology capabilities are creating a robust ecosystem for organoid development, with growing R&D infrastructure and skilled workforce in regenerative medicine.

Rising Clinical Applications :

Growing adoption of human organoids in drug testing, disease modeling, and personalized medicine research is driving demand among Indian research institutions and pharmaceutical companies.

India Human Organoids Market Dynamics

  • The country's thriving biotech ecosystem, combined with government support for advanced healthcare technologies, creates a favorable environment for market expansion.
  • Indian pharmaceutical companies and research institutions are increasingly adopting organoid platforms for preclinical testing and personalized medicine applications.
  • With a CAGR of 17.7% through 2029, India is emerging as a key hub for organoid research in Asia, attracting both domestic and international investments.
  • The convergence of cost-effective research capabilities, skilled scientific talent, and regulatory support positions India to capture significant market share in the global organoids landscape..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • India's human organoids market is valued at $31.4 million in 2024 and is forecast to reach $70.7 million by 2029, growing at a 17.7% CAGR.
    • India's cost-effective research infrastructure and large pharmaceutical sector are accelerating adoption of organoid technologies for drug discovery and development.
    • Government initiatives and academic-industry collaborations in India are strengthening the country's position in regenerative medicine and personalized healthcare.
    • India's expanding life sciences ecosystem positions the country as a key player in the Asia Pacific human organoids market through 2029.

    Human Organoids Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment DEVELOPMENTAL BIOLOGY (Application)
    Forecast Period 2024-2029
    Growth Rate CAGR of 14.4% from 2024 to 2029
    Largest Segment READY-TO-USE PRODUCTS (Type)
    Market Size Base Year (Billions) ~USD 1.19 (2024)
    Revenue Forecast (Billions) ~USD 2.33 (2029)
    Segments Covered Product, Type, Source, Culture Method, Disease Area, Application, End User

    India Human Organoids Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Product

    • Colorectal Models
    • Heart Models
    • Kidney Models
    • Liver Models
    • Lung Models
    • Other Products
    • Pancreatic Models

    By Type

    • 2D Colorectal Models
    • 2D Heart Models
    • 2D Kidney Models
    • 2D Liver Models
    • 2D Lung Models
    • 2D Models (Other Products)
    • 2D Pancreatic Models
    • 3D Bioprinted Colorectal Models
    • 3D Bioprinted Heart Models
    • 3D Bioprinted Kidney Models
    • 3D Bioprinted Liver Models
    • 3D Bioprinted Lung Models
    • 3D Bioprinted Models (Other Products)
    • 3D Bioprinted Pancreatic Models
    • 3D Colorectal Models
    • 3D Heart Models
    • 3D Kidney Models
    • 3D Liver Models
    • 3D Lung Models
    • 3D Models (Other Products)
    • 3D Pancreatic Models
    • Colorectal Organoids
    • Colorectal Spheroids
    • Cryopreserved Cells (Other Products)
    • Cryopreserved Colorectal Cells
    • Cryopreserved Heart Cells
    • Cryopreserved Hepatocytes
    • Cryopreserved Kidney Cells
    • Cryopreserved Lung Cells
    • Cryopreserved Pancreatic Cells
    • Customizable Products
    • Fresh Cells (Other Products)
    • Fresh Colorectal Cells
    • Fresh Heart Cells
    • Fresh Hepatocytes
    • Fresh Kidney Cells
    • Fresh Lung Cells
    • Fresh Pancreatic Cells
    • Heart Organoids
    • Heart Spheroids
    • Kidney Organoids
    • Kidney Spheroids
    • Liver Organoids
    • Liver Spheroids
    • Liver-On-A-Chip
    • Lung Organoids
    • Lung Spheroids
    • Organoids (Other Products)
    • Other 2D Colorectal Models
    • Other 2D Heart Models
    • Other 2D Kidney Models
    • Other 2D Liver Models
    • Other 2D Lung Models
    • Other 2D Models (Other Products)
    • Other 2D Pancreas Models
    • Other 3D Colorectal Models
    • Other 3D Heart Models
    • Other 3D Kidney Models
    • Other 3D Liver Models
    • Other 3D Lung Models
    • Other 3D Models (Other Products)
    • Other 3D Pancreatic Models
    • Pancreatic Organoids
    • Pancreatic Spheroids
    • Ready-To-Use Products
    • Spheroids (Other Products)

    By Source

    • Adult Stem Cells
    • Escs
    • Ipscs
    • Other Sources

    By Culture Method

    • 3D Bioprinting Culture
    • Air-Liquid Interface Culture
    • Matrigel Matrix Culture
    • Other Culture Methods
    • Suspension Culture

    By Disease Area

    • Cardiovascular Diseases
    • Gastrointestinal Diseases
    • Infectious Diseases
    • Liver Diseases
    • Neurological Disorders
    • Oncology
    • Other Disease Areas

    By Application

    • Developmental Biology
    • Disease Pathology
    • Drug Toxicity & Efficacy Testing
    • Other Applications
    • Personalized Medicine
    • Regenerative Medicine

    By End User

    • Academic & Research Institutes
    • Cros
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    INDIA: HUMAN ORGANOIDS MARKET, BY END USER, 2022–2029

    Segment20222023202420252026202720282029CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES7.38.29.210.612.114.116.519.516.1
    CROS1719.221.925.329.334.440.748.517.2
    OTHER END USERS2.52.83.13.544.65.36.214.9
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES202326.731.33744.15364.219.2
    TOTAL46.853.160.970.682.497.2115.5138.417.8

    Target Audience

    • Pharmaceutical Companies : Indian and multinational pharma firms need market intelligence to evaluate organoid adoption for drug development, preclinical testing, and regulatory compliance within India's growing biotech ecosystem.
    • Biotech & Research Institutions : Academic and private research organizations require market data to secure funding, benchmark capabilities, and identify collaboration opportunities in India's expanding organoid research sector.
    • Investment & Venture Capital Firms : Investors seeking high-growth opportunities in India's healthcare sector need detailed market analysis to identify promising organoid startups, research initiatives, and commercialization potential.
    • Medical Device & Diagnostics Companies : Organizations developing complementary technologies require India-specific market insights to understand organoid integration opportunities and partnership potential with local biotech players.
    • Government & Policy Makers : Indian healthcare and biotech policymakers need comprehensive market data to inform regulatory frameworks, funding allocations, and strategic initiatives supporting organoid research and commercialization.

    Reasons to Buy this Report

    • Market Size & Growth Projections : Access precise valuation data for India's organoids market ($31.4M in 2024) with detailed forecasts through 2029, enabling accurate investment planning and resource allocation decisions.
    • Competitive Landscape Analysis : Understand India-specific market dynamics, key players, and competitive positioning within the rapidly expanding organoid sector to identify partnership and investment opportunities.
    • Regulatory & Policy Insights : Gain comprehensive understanding of India's government support mechanisms, biotech policies, and regulatory framework driving organoid market growth and commercialization pathways.
    • Application & End-User Segmentation : Identify high-growth application areas including drug testing, disease modeling, and personalized medicine within Indian pharmaceutical and research institutions for targeted market entry.
    • Strategic Market Entry Planning : Leverage India-specific insights on research infrastructure, talent availability, and cost advantages to develop effective market entry strategies and partnership models.

    Frequently asked questions

    What is the current size of India's human organoids market?

    India's human organoids market was valued at $31.4 million in 2024 and is expected to grow to $70.7 million by 2029.

    What is the projected growth rate for India's human organoids market?

    India's human organoids market is projected to grow at a compound annual growth rate (CAGR) of 17.7% from 2024 to 2029.

    What factors are driving growth in India's human organoids market?

    Growth in India's human organoids market is driven by expanding life sciences infrastructure, cost-effective research capabilities, government support for healthcare innovation, and increasing pharmaceutical industry adoption for drug testing and disease modeling.

    How does India's human organoids market compare to the global market?

    India's human organoids market is growing faster than the global average, with a 17.7% CAGR compared to the global CAGR of 14.4%, reflecting India's emerging strength in regenerative medicine research.

    What role does India play in the Asia Pacific human organoids market?

    India is becoming a key player in the Asia Pacific human organoids market due to its cost-effective research capabilities, large pharmaceutical sector, and growing government investments in advanced healthcare technologies.

    RESEARCH METHODOLOGY

    The study involved major activities in estimating the current market size for the human organoids market. Exhaustive secondary research was done to collect information on the human organoids industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the human organoids market.

    The four steps involved in estimating the market size are

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

    The following is a breakdown of the primary respondents:

    Human Organoids Market

    Note 1: Others include sales managers, marketing managers, and product managers.

    Note 2: Companies are classified into tiers based on their total revenues. As of 2022/2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

    To know about the assumptions considered for the study, download the pdf brochure

    COMPANY NAME DESIGNATION
    Thermo Fisher Scientific Inc. Director of sales
    Merck KGaA Sales Executive

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the human organoids market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • The revenues generated by leading players operating in the human organoids market have been determined through primary and secondary research.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    The research methodology used to estimate the market size includes the following:

    Human Organoids Market

    Data Triangulation

    After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic microanatomy. Organoids are derived from one or a few cells from tissue, embryonic stem cells, or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities.

    Stakeholders

    • Senior Management
    • End User
    • Finance/Procurement Department  
    • R&D Department

    Report Objectives

    • To define, describe, segment, and forecast the global human organoids market, by product, source, type, culture method, disease area, application, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall human organoids market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Middle East & Africa, Latin America, and GCC Countries
    • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
    • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

     

    Get the Full Human Organoids Market Report

    Full forecast, segment splits, and company analysis for all Human Organoids Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status